| First Author | Xu Y | Year | 2021 |
| Journal | Nat Metab | Volume | 3 |
| Issue | 1 | Pages | 59-74 |
| PubMed ID | 33462514 | Mgi Jnum | J:302200 |
| Mgi Id | MGI:6507663 | Doi | 10.1038/s42255-020-00331-1 |
| Citation | Xu Y, et al. (2021) Hepatocyte ATF3 protects against atherosclerosis by regulating HDL and bile acid metabolism. Nat Metab 3(1):59-74 |
| abstractText | Activating transcription factor (ATF)3 is known to have an anti-inflammatory function, yet the role of hepatic ATF3 in lipoprotein metabolism or atherosclerosis remains unknown. Here we show that overexpression of human ATF3 in hepatocytes reduces the development of atherosclerosis in Western-diet-fed Ldlr(-/-) or Apoe(-/-) mice, whereas hepatocyte-specific ablation of Atf3 has the opposite effect. We further show that hepatic ATF3 expression is inhibited by hydrocortisone. Mechanistically, hepatocyte ATF3 enhances high-density lipoprotein (HDL) uptake, inhibits intestinal fat and cholesterol absorption and promotes macrophage reverse cholesterol transport by inducing scavenger receptor group B type 1 (SR-BI) and repressing cholesterol 12alpha-hydroxylase (CYP8B1) in the liver through its interaction with p53 and hepatocyte nuclear factor 4alpha, respectively. Our data demonstrate that hepatocyte ATF3 is a key regulator of HDL and bile acid metabolism and atherosclerosis. |
